EUVIMEDEUVIMED entdecken
Scoping ReviewOpen Access · CC BY-NC-SA 4.0

Ex vivo microscopic testicular sperm extraction at the time of radical orchiectomy in men with nonobstructive azoospermia (NOA): a scoping review

Carlo Giulioni, Nguyen Ho Vinh Phuoc, Selahittin Cayan

Asian Journal of Andrology · 2025-05 · 27 (3) · 416-422

DOI: 10.4103/aja202387 ↗

Kurz gefasst

Scoping Review in der Zeitschrift Asian Journal of Andrology, online erschienen am 06.02.2024. Verfasst von Carlo Giulioni und 2 weiteren Autor:innen. Beteiligte Einrichtung: Polytechnic University of Marche, Department of Urology, Ancona 60126, Italy. Hauptthemen laut MEDLINE: Azoospermia, Sperm Retrieval, Orchiectomy, Testicular Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Testicular tumor is the most common solid malignancy in males under 40 years of age. This malignancy is known to have a negative impact on male fertility. Therefore, several techniques for sperm retrieval have been proposed, including microdissection testicular sperm extraction (mTESE). The objective of this study was to review the literature on the outcomes of oncological (Onco)-mTESE at the time of radical orchiectomy. We conducted a comprehensive literature search through PubMed, Scopus, and Cochrane Central Controlled Register of Trials. Only studies reporting ex vivo mTESE in patients with testicular tumor were considered. Twelve papers met the inclusion criteria and were included in this review. Tumor size was identified as the sole preoperative factor influencing spermatogenesis. The considered studies demonstrated a satisfactory success rate for Onco-mTESE, associated with a similarly valid percentage of live healthy births through assisted reproductive technology. Currently, no comparison has been made between Onco-mTESE and conventional Onco-TESE, hence further assessment is required. In cases where the tumor completely replaces the cancer-bearing testicle, a contralateral micro-TESE may be a viable alternative. However, the surgeon should evaluate associated risks and benefits preoperatively. In conclusion, Onco-mTESE at the time of radical orchiectomy appears to be a promising therapeutic option for young patients with testicular tumors. Nevertheless, additional studies are necessary to achieve a definitive conclusion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AzoospermiaSperm RetrievalOrchiectomyTesticular NeoplasmsHumansMaleMicrodissectionTestisAdult

Stichwörter der Autor:innen

assisted reproductive technologymicrodissection testicular sperm extractionradical orchiectomytesticular tumor

Autor:innen und Institutionen

  • Polytechnic University of Marche, Department of Urology, Ancona 60126, Italy.
  • Global Andrology Forum, Moreland Hills, OH 44022, USA.
  • Department of Andrology, Binh Dan Hospital, Ho Chi Minh City 008408, Vietnam.
  • University of Mersin School of Medicine, Department of Urology, Mersin 33260, Turkey.

Zitieren

APA

Giulioni, C., Phuoc, N. H. V., & Cayan, S. (2025). Ex vivo microscopic testicular sperm extraction at the time of radical orchiectomy in men with nonobstructive azoospermia (NOA): a scoping review. Asian Journal of Andrology, 27(3), 416-422. https://doi.org/10.4103/aja202387

Vancouver

Giulioni C, Phuoc NHV, Cayan S. Ex vivo microscopic testicular sperm extraction at the time of radical orchiectomy in men with nonobstructive azoospermia (NOA): a scoping review. Asian Journal of Andrology. 2025;27(3):416-422. doi:10.4103/aja202387

BibTeX
@article{Giulioni2025,
  author = {Giulioni, Carlo and Phuoc, Nguyen Ho Vinh and Cayan, Selahittin},
  title = {Ex vivo microscopic testicular sperm extraction at the time of radical orchiectomy in men with nonobstructive azoospermia (NOA): a scoping review},
  journal = {Asian Journal of Andrology},
  year = {2025},
  volume = {27},
  number = {3},
  pages = {416--422},
  doi = {10.4103/aja202387}
}
Kostenlos starten →